Liquid biopsies, comprising the noninvasive analysis of circulating tumor-derived material
(the 'tumor circulome'), represent an innovative tool in precision oncology to overcome …

There is a growing trend towards exploring the use of a minimally invasive “liquid biopsy” to
identify biomarkers in a number of cancers, including urologic malignancies. Multiple …

Cancer diagnosis and therapeutics (theranostics) based on the tumor microenvironment
(TME) and biomarkers has been an emerging approach for precision medicine. DNA …

Diagnosing, selecting therapy for, and monitoring cancer in patients using a minimally
invasive blood test represents a significant advance in precision medicine. Wide variability …

Exosomes have emerged as a novel approach for the treatment and diagnosis of cancer
after RNA content was discovered in exosomes in 2007. As important meditators of …

As an essential part of central dogma, RNA delivers genetic and regulatory information and
reflects cellular states. Based on high-throughput sequencing technologies, cumulating data …

Despite its early promise as a diagnostic and prognostic tool, gene expression profiling
remains cost-prohibitive and challenging to implement in a clinical setting. Here, we …

Tumor heterogeneity is a major challenge and the root cause of resistance to treatment. Still,
the standard diagnostic approach relies on the analysis of a single tumor sample from a …

Pancreatic cancer remains difficult to treat and has a high mortality rate. It is difficult to
diagnose early, mainly due to the lack of screening imaging modalities and specific …

Circulating nucleic acids are found in free form in body fluids and may serve as minimally
invasive tools for cancer diagnosis and prognosis. Only a few studies have investigated the …